PALO ALTO, Calif., Oct. 21, 2018 /PRNewswire/ -- Varian (NYSE: VAR)
today announced the Bravos™ afterloader system for High
Dose Rate (HDR) brachytherapy treatments. Based on over five years
of in-clinic research, Bravos is an integrated system designed to
improve the patient and clinic experience by simplifying
brachytherapy treatment and providing greater workflow
efficiency.
HDR brachytherapy involves delivering radiotherapy by
temporarily placing a tiny radioactive source directly into the
tumor or other targeted area. Using an afterloader, clinicians are
able to position the radioactive source in a needle, catheter or
tumor-specific applicator following a pattern that has been
designed to create a highly conformal dose distribution within or
on the surface of the patient's anatomy. Once the treatment is
completed, the afterloader safely returns the source to the
afterloader.
To simplify the treatment process, the Bravos afterloader
features a touchscreen control and instinctive LED lights. The
touchscreen provides easy access to patient treatment information
on the afterloader, eliminating the need for the clinician to leave
the room to retrieve patient and treatment information. The green,
yellow and red LED lights on Bravos guide clinicians through the
correct connection process of the transfer guide tubes. The green
lights signal a proper connection and the yellow and red lights
alert the clinician to areas needing correction.
To help increase efficiency of the treatment process, Bravos
features a customizable pre-treatment checklist on the touchscreen.
Like surgical procedures, the customizable checklist allows the
clinician to set a review process including a time-out for patient
safety, and e-signatures for speed and accuracy.
"We are excited about the capabilities of Bravos and have
already begun treating patients in our department," said
Vicki Currie, lead Brachytherapy
Physicist, Norfolk & Norwich
University Hospital. "As we continue to use and learn the
features in this new system, the clinical efficiencies will enable
us to improve our Brachytherapy workflow."
"After spending time in clinics around the world talking with
the treatment teams, we saw the opportunity to create a system that
is easy to use and creates greater efficiencies, allowing
clinicians to spend more time with the patient," said Ed Vertatschitsch, vice president, Global
Portfolio Solutions, Varian. "Bravos is a big step forward for
brachytherapy treatments and we will continue to collaborate with
our partners in achieving new victories against cancer."
Bravos integrates with Varian's BrachyVision™ for
treatment planning and offers interoperability with Varian
ARIA® oncology information system. Bravos has received
CE mark and FDA 510(k) clearance.
For more information on Bravos visit www.varian.com/bravos.
About Varian
Varian is a leader in developing and
delivering cancer care solutions and is focused on creating a world
without fear of cancer. Headquartered in Palo Alto, California, Varian employs
approximately 7,000 people around the world. For more
information, visit http://www.varian.com and follow @VarianMedSys
on Twitter.
Press Contact
Mark Plungy
Director, Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-unveils-new-bravos-afterloader-system-for-brachytherapy-treatments-300734669.html
SOURCE Varian